Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial
Active, not recruiting
Novo Nordisk A/S
Phase 4
2018-07-13
The main purpose of this study is to compare the effects of semaglutide (Ozempic®) with the
effects of other treatments for type 2 diabetes in a normal practice setting. The participant
will be assigned by chance (like flipping a coin) to one of the following treatment groups:
Group 1: semaglutide (Ozempic®) (by injection into skin) Group 2: standard of care
antidiabetic medication (oral or injectable). The participant has an equal chance of being in
either of the treatment groups. Neither the participant nor the study doctor or study staff
will be able to pick which group the participant is in, but the participant will know which
study drug the participant has been assigned to. The study doctor will provide the
participant with a prescription for the study diabetes medication based on the treatment
group the participant is assigned. The participation will last about 2 years.
A Study Comparing the Dulaglutide Pen and the Semaglutide Pen
Completed
Eli Lilly and Company
Phase 4
2018-10-18
In this study participants will try out two different types of drug injection pens
(dulaglutide and semaglutide) on a practice pad and decide which device they prefer. No study
drug will be administered.
To assess whether the addition of dapagliflozin to semaglutide and insulin (triple therapy)
improves glycemic control in patients with type 1 diabetes compared with semaglutide and
insulin (dual therapy) and insulin only (standard) treatment.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
